Rolitetracycline


Concise Prescribing Info
Contraindications
Hypersensitivity; SLE; renal impairment; pregnancy, lactation; children ≤8 yr.
Special Precautions
Myasthenia gravis; avoid direct sunlight; elderly; hepatic impairment. Serum monitoring is recommended.
Adverse Reactions
GI disturbances; dry mouth; glossitis; tongue or teeth discoloration; stomatitis; dysphagia; oesophageal ulceration; oral candidiasis; vulvovaginitis; pruritus; enterocolitis; renal dysfunction; enamel hypoplasia; increased intracranial pressure with headache, visual disturbances and papilloedema (discontinue); bulging fontanelles in infants; hypersensitivity; nail discoloration; onycholysis; abnormal skin pigmentation. Shivering, peculiar taste sensation following injection; rapid IV inj may cause transient giddiness, hot flushes, reddening of the face and peripheral circulatory failure.
Potentially Fatal: Pseudomembranous colitis.
Drug Interactions
Diuretics, methoxyflurane and other potentially nephrotoxic drugs increase risk of nephrotoxicity. Increased risk of benign intracranial hypertension when used with retinoids. Decreases plasma concentrations of atovaquone. Ocular preparations containing thiomersal increase risk of ocular inflammation. May decrease efficacy of oral contraceptives.
Potentially Fatal: Increased toxic effects of ergot alkaloids and methotrexate.
Food Interaction
Dairy and milk products.
Lab Interference
May interfere with determination of urinary catecholamines or glucose.
Action
Description: Rolitetracycline prevents the binding of aminoacyl transfer RNA and inhibits protein synthesis and hence cell growth. It has a broad spectrum of antimicrobial activity which includes chlamydias, rickettsias, spirochetes, many aerobic and anaerobic gram-negative and gram-positive pathogenic bacteria and some protozoa.
Pharmacokinetics:
Absorption: Reaches peak concentrations about 2-6 hr after IV admin.
Excretion: Half-life: about 5-8 hr. >50% eliminated via the urinary route.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Rolitetracycline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in